Asset
ACAZICOLCEPT
Vertex Pharmaceuticals Incorporated Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04835441 | phase2 | completed | 2021-06-22 | 2024-07-09 | Alpine Immune Sciences Inc, A Subsidiary of Vertex | ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus |
| NCT04227938 | phase1 | terminated | 2020-05-11 | 2020-05-21 | Alpine Immune Sciences, Inc. | ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD |
| NCT03748836 | phase1 | completed | 2019-01-29 | 2019-11-18 | Alpine Immune Sciences, Inc. | Adult Healthy Volunteers Study to Evaluate ALPN-101 Safety |
FDA applications (0)
This company has no applications containing this asset.